CY1121279T1 - Ετεροκυκλικη ενωση - Google Patents

Ετεροκυκλικη ενωση

Info

Publication number
CY1121279T1
CY1121279T1 CY20191100202T CY191100202T CY1121279T1 CY 1121279 T1 CY1121279 T1 CY 1121279T1 CY 20191100202 T CY20191100202 T CY 20191100202T CY 191100202 T CY191100202 T CY 191100202T CY 1121279 T1 CY1121279 T1 CY 1121279T1
Authority
CY
Cyprus
Prior art keywords
compound
heterocycle
union
salt
medicament
Prior art date
Application number
CY20191100202T
Other languages
Greek (el)
English (en)
Inventor
Shizuo Kasai
Takashi Nakahata
Asato Kina
Hideki Hirose
Takeshi Yamasaki
Tohru Yamashita
Yoichi Nishikawa
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of CY1121279T1 publication Critical patent/CY1121279T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CY20191100202T 2013-10-29 2019-02-14 Ετεροκυκλικη ενωση CY1121279T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013224093 2013-10-29
PCT/JP2014/005438 WO2015064083A1 (en) 2013-10-29 2014-10-28 Heterocyclic compound

Publications (1)

Publication Number Publication Date
CY1121279T1 true CY1121279T1 (el) 2020-05-29

Family

ID=51932560

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100202T CY1121279T1 (el) 2013-10-29 2019-02-14 Ετεροκυκλικη ενωση

Country Status (19)

Country Link
US (1) US9120777B2 (enExample)
EP (1) EP3063139B1 (enExample)
JP (1) JP6450755B2 (enExample)
AR (2) AR098215A1 (enExample)
CY (1) CY1121279T1 (enExample)
DK (1) DK3063139T3 (enExample)
ES (1) ES2710657T3 (enExample)
HR (1) HRP20190133T1 (enExample)
HU (1) HUE041792T2 (enExample)
LT (1) LT3063139T (enExample)
PL (1) PL3063139T3 (enExample)
PT (1) PT3063139T (enExample)
RS (1) RS58321B1 (enExample)
SI (1) SI3063139T1 (enExample)
SM (1) SMT201900101T1 (enExample)
TR (1) TR201901986T4 (enExample)
TW (1) TWI668214B (enExample)
UY (1) UY35801A (enExample)
WO (1) WO2015064083A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013122029A1 (ja) * 2012-02-13 2013-08-22 武田薬品工業株式会社 芳香環化合物
US9605000B2 (en) 2013-03-14 2017-03-28 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
US20230049619A1 (en) * 2019-12-19 2023-02-16 Universite De Strasbourg Sigma-1 receptor ligands and uses thereof
WO2022052958A1 (en) 2020-09-10 2022-03-17 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN116354961B (zh) * 2021-12-27 2025-07-25 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其药物组合物及用途
WO2024204277A1 (ja) 2023-03-27 2024-10-03 株式会社スコヒアファーマ 成長ホルモン分泌促進剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356906A (en) 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
WO2001096308A1 (en) 2000-06-12 2001-12-20 Eisai Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
CN1902171A (zh) 2003-11-10 2007-01-24 舍林股份公司 用作ccr-5拮抗剂的苄醚胺化合物
KR101117931B1 (ko) * 2006-08-15 2012-04-12 에프. 호프만-라 로슈 아게 페닐, 피리딘 및 퀴놀린 유도체
US7862825B2 (en) 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
US7799806B2 (en) 2007-04-04 2010-09-21 Hoffmann-La Roche Inc. Substituted n-benzyl piperidines as somatostatin receptor modulators
US20080306116A1 (en) 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
TW200918062A (en) 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
WO2010129729A1 (en) 2009-05-07 2010-11-11 Merck Sharp & Dohme Corp. Substituted spirocyclic amines useful as antidiabetic compounds
US8742110B2 (en) 2010-08-18 2014-06-03 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
US9000175B2 (en) 2010-11-26 2015-04-07 Lupin Limited Bicyclic GPR119 modulators
US9605000B2 (en) 2013-03-14 2017-03-28 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as SSTR antagonists

Also Published As

Publication number Publication date
LT3063139T (lt) 2019-02-25
EP3063139A1 (en) 2016-09-07
WO2015064083A1 (en) 2015-05-07
PL3063139T3 (pl) 2019-05-31
AR128158A2 (es) 2024-03-27
UY35801A (es) 2015-06-30
US20150119412A1 (en) 2015-04-30
EP3063139B1 (en) 2018-11-21
JP2016535040A (ja) 2016-11-10
PT3063139T (pt) 2019-02-22
ES2710657T3 (es) 2019-04-26
TR201901986T4 (tr) 2019-03-21
HUE041792T2 (hu) 2019-05-28
TW201542539A (zh) 2015-11-16
TWI668214B (zh) 2019-08-11
DK3063139T3 (en) 2019-03-11
SI3063139T1 (sl) 2019-03-29
US9120777B2 (en) 2015-09-01
RS58321B1 (sr) 2019-03-29
SMT201900101T1 (it) 2019-02-28
AR098215A1 (es) 2016-05-18
JP6450755B2 (ja) 2019-01-09
HRP20190133T1 (hr) 2019-03-22

Similar Documents

Publication Publication Date Title
CY1121534T1 (el) Ενωσεις διυδροβενζοφουρανιου χρησιμες στην αγωγη του διαβητη και της παχυσαρκιας
CY1124790T1 (el) Ενωση πεπτιδιου
CY1123842T1 (el) Ετεροαρυλικες ενωσεις για τη θεραπευτικη αντιμετωπιση οφθαλμικων νοσων
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
CY1124374T1 (el) Ενωση αρυλαζολιου και παραγοντας ελεγχου παρασιτων
CY1120173T1 (el) Ενωση πυραζολο-αμιδιου και φαρμακευτικες χρησεις αυτης
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
CY1121163T1 (el) Ανταγωνιστες υποδοχεα σωματοστατινης υποτυπου 5 (sstr5)
PH12016501614A1 (en) Heterocyclic compound
DK3192451T3 (da) Medicinsk krog
EA201692219A1 (ru) Способы получения противовирусных соединений
CY1122971T1 (el) Ενωσεις διυδροπυριμιδιν-2-ονης και ιaτρικη χρηση αυτων
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
CY1119583T1 (el) Φαινοξυαιθυλο παραγωγα κυκλικης αμινης και η δραστικοτητα τους ως τροποποιητες του ερ4 υποδοχεα
DK3230281T3 (da) 1,3-thiazol-2-yl-substituerede benzamider
AR128158A2 (es) Compuesto heterocíclico
MX2016015856A (es) Derivados de naftiridinadiona.
CY1120142T1 (el) Ενωσεις αζετιδινυλοξυφαινυλοπυρρολiδινης
MX379401B (es) Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
RU2013142539A (ru) Ароматические полиэфиры
CY1119540T1 (el) Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt
MX2015012610A (es) Pacritinib deuterizado.
RU2013142538A (ru) Ароматические полиэфирсульфонкетоны
CY1121388T1 (el) Παραγωγα βενζυλυδροξειδιου, παρασκευη αυτων και θεραπευτικη χρηση αυτων